CHICAGO (Reuters) - Patients with advanced multiple myeloma treated with bluebird bio's experimental immunotherapy lived for a median of nearly a year before their cancer worsened, according to data from a small study presented on Friday.
from Reuters: Health News https://ift.tt/2LdeQiE
0 comments:
Post a Comment